FDA Accepts Purified Cortrophin Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome
1 September 2021 - - US-based biopharmaceutical company ANI Pharmaceuticals, Inc's (NASDAQ: ANIP) supplemental New Drug Application for Purified Cortrophin Gel has been accepted by the US Food and Drug Administration for review, the company said.

Purified Cortrophin Gel (Repository Corticotropin Injection USP) is a purified adrenocorticotropic hormone previously approved in the US for multiple indications including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome.

ANI Pharmaceuticals is in developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products.

Its team is focused on delivering sustainable growth by building a successful Purified Cortrophin Gel franchise, strengthening its generics business with enhanced development capability, innovation in established brands and leveraging the company's North American manufacturing capabilities.


Related Headlines